文章摘要
张铁峰,蔚 佩,何 元,周 菁,苏 伟.右美托咪定联合舒芬太尼术后镇痛对卵巢癌根治术患者细胞免疫功能和炎症应激反应的影响[J].,2023,(24):4751-4754
右美托咪定联合舒芬太尼术后镇痛对卵巢癌根治术患者细胞免疫功能和炎症应激反应的影响
Effects of of Dexmedetomidine Combined with Sufentanil for Postoperative Analgesia on Cellular Immune Function and Inflammatory Stress Response in Patients Undergoing Radical Ovarian Cancer Surgery
投稿时间:2023-05-23  修订日期:2023-06-17
DOI:10.13241/j.cnki.pmb.2023.24.030
中文关键词: 右美托咪定  舒芬太尼  术后镇痛  卵巢癌根治术  细胞免疫功能  炎症应激反应
英文关键词: Dexmetomidine  Sufentanil  Postoperative analgesia  Radical ovarian cancer surgery  Cellular immune function  Inflammatory stress response
基金项目:陕西省卫生健康委科研基金项目(2021D036)
作者单位E-mail
张铁峰 陕西省肿瘤医院麻醉科 陕西 西安 710065 ZhangTiefeng_2005@163.com 
蔚 佩 陕西省肿瘤医院麻醉科 陕西 西安 710065  
何 元 陕西省肿瘤医院麻醉科 陕西 西安 710065  
周 菁 陕西省肿瘤医院麻醉科 陕西 西安 710065  
苏 伟 陕西省肿瘤医院麻醉科 陕西 西安 710065  
摘要点击次数: 38
全文下载次数: 46
中文摘要:
      摘要 目的:探讨右美托咪定联合舒芬太尼术后镇痛对卵巢癌根治术患者细胞免疫功能和炎症应激反应的影响。方法:根据随机数字表法将2020年2月至2023年2月期间陕西省肿瘤医院120例择期行卵巢癌根治术的患者分为对照组(n=60,术后镇痛药物选用舒芬太尼)和研究组(n=60,术后镇痛药物选用右美托咪定联合舒芬太尼)。对比两组镇静(Ramsay镇静评分)、细胞免疫功能[CD3+、CD4+、CD8+、CD4+/CD8+]、镇痛情况[视觉模拟评分法(VAS)]、不良反应、炎症应激反应[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、皮质醇(Cor)和去甲肾上腺素(NE)]变化情况。结果:与对照组术后6 h、12 h、24 h、48 h 相比,研究组同时间点VAS评分更低,Ramsay镇静评分更高(P<0.05)。与对照组术后24 h相比,研究组同时间点CD3+、CD4+、CD4+/CD8+更高,CD8+更低(P<0.05)。两组不良反应发生率组间对比未见差异(P>0.05)。与对照组术后24 h相比,研究组同时间点IL-6、TNF-α、Cor、NE更低(P<0.05)。结论:右美托咪定联合舒芬太尼用于卵巢癌根治术患者术后镇痛,镇静、镇痛效果显著,同时还可减轻机体炎症应激反应,缓解免疫抑制。
英文摘要:
      ABSTRACT Objective: To explore the effects of dexmedetomidine combined with sufentanil for postoperative analgesia on cellular immune function and inflammatory stress response in patients undergoing radical ovarian cancer surgery. Methods: 120 patients who were selected for radical ovarian cancer surgery in Shaanxi Cancer Hospital from February 2020 to February 2023 were divided into the control group (n=60, sufentanil was used as postoperative analgesic) and the study group (n=60, dexmedetomidine combined with sufentanil was used as postoperative analgesic) according to the method of random number table.The sedation (Ramsay sedation score), cellular immune function [CD3+, CD4+, CD8+, CD4+/CD8+], analgesia situation [visual analogue scale (VAS)], adverse reactions, inflammatory stress response [interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), Cortisol (Cor) and norepinephrine (NE)] in the two groups were compared. Results: Compared with the control group at 6 h, 12 h, 24 h, and 48 h after surgery, the study group had lower VAS score, and higher Ramsay sedation score at the same time point (P<0.05). Compared with the control group at 24 h after surgery, the study group had higher CD3+, CD4+, CD4+/CD8+, and lower CD8+ at the same time point(P<0.05). There was no difference in the incidence of adverse reactions in the two groups(P>0.05). Compared with the control group at 24 h after surgery, the study group had lower IL-6 and TNF-α, Cor, NE at the same time point(P<0.05). Conclusion: Dexmedetomidine combined with Sufentanil are used for postoperative analgesia in patients undergoing radical ovarian cancer surgery, with significant sedative and analgesic effects. At the same time, they can also reduce the body's inflammatory stress response, and alleviate immune suppression.
查看全文   查看/发表评论  下载PDF阅读器
关闭